Point72 Hong Kong LTD Replimune Group, Inc. Transaction History

Point72 Hong Kong LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$15.6 - $21.15 $41,496 - $56,258	2,660 Added 449.32%	3,252 $56,000
Q2 2022 Aug 15, 2022	SELL	$13.32 - $19.98 $84,275 - $126,413	-6,327 Reduced 91.44%	592 $10,000
Q1 2022 May 16, 2022	BUY	$15.24 - $29.75 $82,997 - $162,018	5,446 Added 369.72%	6,919 $117,000
Q4 2021 Feb 14, 2022	SELL	$25.43 - $34.25 $55,564 - $74,836	-2,185 Reduced 59.73%	1,473 $40,000
Q3 2021 Nov 15, 2021	BUY	$28.98 - $39.54 $106,008 - $144,637	3,658 New	3,658 $108,000
Q1 2020 May 15, 2020	SELL	$8.9 - $19.08 $9,985 - $21,407	-1,122 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$11.61 - $17.21 $13,026 - $19,309	1,122 New	1,122 $16,000

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $631M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

Stay updated on Point72 Hong Kong LTD with notifications on news.